169 related articles for article (PubMed ID: 37022888)
21. Polyaspartic acid-anchored mesoporous silica nanoparticles for pH-responsive doxorubicin release.
Hakeem A; Zahid F; Zhan G; Yi P; Yang H; Gan L; Yang X
Int J Nanomedicine; 2018; 13():1029-1040. PubMed ID: 29497295
[TBL] [Abstract][Full Text] [Related]
22. Chitosan-capped mesoporous silica nanoparticles as pH-responsive nanocarriers for controlled drug release.
Hu X; Wang Y; Peng B
Chem Asian J; 2014 Jan; 9(1):319-27. PubMed ID: 24115568
[TBL] [Abstract][Full Text] [Related]
23. Mesoporous silica nanoparticles: synthesis, classification, drug loading, pharmacokinetics, biocompatibility, and application in drug delivery.
Li Z; Zhang Y; Feng N
Expert Opin Drug Deliv; 2019 Mar; 16(3):219-237. PubMed ID: 30686075
[TBL] [Abstract][Full Text] [Related]
24. A Review on Recent Technologies and Patents on Silica Nanoparticles for Cancer Treatment and Diagnosis.
Gupta A; Kushwaha SS; Mishra A
Recent Pat Drug Deliv Formul; 2020; 14(2):126-144. PubMed ID: 32928094
[TBL] [Abstract][Full Text] [Related]
25. Increasing the cytotoxicity of doxorubicin in breast cancer MCF-7 cells with multidrug resistance using a mesoporous silica nanoparticle drug delivery system.
Wang X; Teng Z; Wang H; Wang C; Liu Y; Tang Y; Wu J; Sun J; Wang H; Wang J; Lu G
Int J Clin Exp Pathol; 2014; 7(4):1337-47. PubMed ID: 24817930
[TBL] [Abstract][Full Text] [Related]
26. Prolonged proliferation and delayed senescence of the adipose-derived stem cells grown on the electrospun composite nanofiber co-encapsulated with TiO
Pourpirali R; Mahmoudnezhad A; Oroojalian F; Zarghami N; Pilehvar Y
Int J Pharm; 2021 Jul; 604():120733. PubMed ID: 34044059
[TBL] [Abstract][Full Text] [Related]
27. Dual response to pH and chiral microenvironments for the release of a flurbiprofen-loaded chiral self-assembled mesoporous silica drug delivery system.
Wu L; Gou K; Guo X; Guo Y; Chen M; Hou J; Li S; Li H
Colloids Surf B Biointerfaces; 2021 Mar; 199():111501. PubMed ID: 33338882
[TBL] [Abstract][Full Text] [Related]
28. Erythrocyte-cancer Hybrid Membrane-camouflaged Mesoporous Silica Nanoparticles Loaded with Gboxin for Glioma-targeting Therapy.
Jiao X; Yu X; Gong C; Zhu H; Zhang B; Wang R; Yuan Y
Curr Pharm Biotechnol; 2022; 23(6):835-846. PubMed ID: 34825635
[TBL] [Abstract][Full Text] [Related]
29. Morin Hydrate Encapsulation and Release from Mesoporous Silica Nanoparticles for Melanoma Therapy.
Cunha C; Marinheiro D; Ferreira BJML; Oliveira H; Daniel-da-Silva AL
Molecules; 2023 Jun; 28(12):. PubMed ID: 37375331
[TBL] [Abstract][Full Text] [Related]
30. An anti-ROS/hepatic fibrosis drug delivery system based on salvianolic acid B loaded mesoporous silica nanoparticles.
He Q; Zhang J; Chen F; Guo L; Zhu Z; Shi J
Biomaterials; 2010 Oct; 31(30):7785-96. PubMed ID: 20674009
[TBL] [Abstract][Full Text] [Related]
31. Effects of Silymarin-Loaded Nanoparticles on HT-29 Human Colon Cancer Cells.
Mombeini M; Saki G; Khorsandi L; Bavarsad N
Medicina (Kaunas); 2018 Mar; 54(1):. PubMed ID: 30344232
[No Abstract] [Full Text] [Related]
32. Co-Delivery of Epirubicin and siRNA Using Functionalized Mesoporous Silica Nanoparticles Enhances In vitro and In vivo Drug Efficacy.
Hanafi-Bojd MY; Jaafari MR; Ramezanian N; Abnous K; Malaekeh-Nikouei B
Curr Drug Deliv; 2016; 13(7):1176-1182. PubMed ID: 26718488
[TBL] [Abstract][Full Text] [Related]
33. Mesoporous silica coated SPIONs containing curcumin and silymarin intended for breast cancer therapy.
Sadegha S; Varshochian R; Dadras P; Hosseinzadeh H; Sakhtianchi R; Mirzaie ZH; Shafiee A; Atyabi F; Dinarvand R
Daru; 2022 Dec; 30(2):331-341. PubMed ID: 36197594
[TBL] [Abstract][Full Text] [Related]
34. Targeted combined therapy in 2D and 3D cultured MCF-7 cells using metformin and erlotinib-loaded mesoporous silica magnetic nanoparticles.
Hashemzadeh N; Aghanejad A; Dalir Abdolahinia E; Dolatkhah M; Barzegar-Jalali M; Omidi Y; Barar J; Adibkia K
J Microencapsul; 2021; 38(7-8):472-485. PubMed ID: 34511038
[TBL] [Abstract][Full Text] [Related]
35. Folic acid-hydrophilic polymer coated mesoporous silica nanoparticles target doxorubicin delivery.
Al-Nadaf AH; Dahabiyeh LA; Jawarneh S; Bardaweel S; Mahmoud NN
Pharm Dev Technol; 2021 Jun; 26(5):582-591. PubMed ID: 33729906
[TBL] [Abstract][Full Text] [Related]
36. Controlled synthesis and size effects of multifunctional mesoporous silica nanosystem for precise cancer therapy.
Ma B; He L; You Y; Mo J; Chen T
Drug Deliv; 2018 Nov; 25(1):293-306. PubMed ID: 29334793
[TBL] [Abstract][Full Text] [Related]
37. YSA-conjugated mesoporous silica nanoparticles effectively target EphA2-overexpressing breast cancer cells.
Liu Z; Tao Z; Zhang Q; Wan S; Zhang F; Zhang Y; Wu G; Wang J
Cancer Chemother Pharmacol; 2018 Apr; 81(4):687-695. PubMed ID: 29392452
[TBL] [Abstract][Full Text] [Related]
38. Synchronized Ratiometric Codelivery of Metformin and Topotecan through Engineered Nanocarrier Facilitates In Vivo Synergistic Precision Levels at Tumor Site.
Banala VT; Sharma S; Barnwal P; Urandur S; Shukla RP; Ahmad N; Mittapelly N; Pandey G; Dwivedi M; Kalleti N; Mitra K; Rath SK; Trivedi R; Mishra PR
Adv Healthc Mater; 2018 Oct; 7(19):e1800300. PubMed ID: 30102470
[TBL] [Abstract][Full Text] [Related]
39. Tailor-made pH-sensitive polyacrylic acid functionalized mesoporous silica nanoparticles for efficient and controlled delivery of anti-cancer drug Etoposide.
Saroj S; Rajput SJ
Drug Dev Ind Pharm; 2018 Jul; 44(7):1198-1211. PubMed ID: 29412022
[TBL] [Abstract][Full Text] [Related]
40. Synthesis of lactoferrin mesoporous silica nanoparticles for pemetrexed/ellagic acid synergistic breast cancer therapy.
Ali OM; Bekhit AA; Khattab SN; Helmy MW; Abdel-Ghany YS; Teleb M; Elzoghby AO
Colloids Surf B Biointerfaces; 2020 Apr; 188():110824. PubMed ID: 32023511
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
